Affiliation:
1. University of Edinburgh
2. Hospital Clínic of Barcelona
3. Hospital Clinic of Barcelona
4. Hospital Clinic at the University of Barcelona.
Abstract
Abstract
Mood disorders (MDs) are among the leading causes of disease burden worldwide. Limited specialized care availability remains a major bottleneck thus hindering pre-emptive interventions. MDs manifest with changes in mood, sleep, and motor activity, observable in ecological physiological recordings thanks to recent advances in wearable technology. Therefore, near-continuous and passive collection of physiological data from wearables in daily life, analyzable with machine learning (ML), could mitigate this problem, bringing mood disorders monitoring outside the clinician’s office. Previous works predict a single label, either the disease state or a psychometric scale total score. However, clinical practice suggests that the same label may underlie different symptom profiles, requiring specific treatments. Here we bridge this gap by proposing a new task: inferring all items in HDRS and YMRS, the two most widely used standardized scales for assessing MDs symptoms, using physiological data from wearables. To that end, we develop a deep learning pipeline to score the symptoms of a large cohort of MD patients and show that agreement between predictions and assessments by an expert clinician is clinically significant (quadratic Cohen’s κ and macro-average F1 score both of 0.609). While doing so, we investigate several solutions to the ML challenges associated with this task, including multi-task learning, class imbalance, ordinal target variables, and cross-subject invariant representations. Lastly, we illustrate the importance of testing on out-of-distribution samples.
Publisher
Research Square Platform LLC
Reference65 articles.
1. American Psychiatric Association D, Association AP, others. Diagnostic and statistical manual of mental disorders: DSM-5. American psychiatric association Washington, DC, 2013.
2. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic;Santomauro DF;The Lancet,2021
3. The economic burden of adults with major depressive disorder in the United States (2010 and 2018);Greenberg PE;Pharmacoeconomics,2021
4. Bipolar disorders;Vieta E;Nat Rev Dis Primer,2018
5. A rating scale for depression;Hamilton M;J Neurol Neurosurg Psychiatry,1960